The estimated Net Worth of John Patrick Mueller is at least 698 千$ dollars as of 19 October 2021. Dr Mueller owns over 4,001 units of Entasis Therapeutics Inc stock worth over 100,738$ and over the last 6 years he sold ETTX stock worth over 12,763$. In addition, he makes 584,548$ as Chief Devel. Officer at Entasis Therapeutics Inc.
Dr has made over 1 trades of the Entasis Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 4,001 units of ETTX stock worth 12,763$ on 19 October 2021.
The largest trade he's ever made was selling 4,001 units of Entasis Therapeutics Inc stock on 19 October 2021 worth over 12,763$. On average, Dr trades about 445 units every 0 days since 2018. As of 19 October 2021 he still owns at least 45,999 units of Entasis Therapeutics Inc stock.
You can see the complete history of Dr Mueller stock trades at the bottom of the page.
Dr. John Patrick Mueller Ph.D. is the Chief Devel. Officer at Entasis Therapeutics Inc.
As the Chief Devel. Officer of Entasis Therapeutics Inc, the total compensation of Dr D at Entasis Therapeutics Inc is 584,548$. There are 2 executives at Entasis Therapeutics Inc getting paid more, with Dr. Manoussos Perros having the highest compensation of 934,846$.
Dr D is 61, he's been the Chief Devel. Officer of Entasis Therapeutics Inc since . There are no older and 7 younger executives at Entasis Therapeutics Inc.
John's mailing address filed with the SEC is C/O ENTASIS THERAPEUTICS HOLDINGS INC.,, 35 GATEHOUSE DRIVE, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Entasis Therapeutics Inc have traded over 348,925$ worth of Entasis Therapeutics Inc stock and bought 50,891,639 units worth 170,673,776$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Inc.Innoviva Strategic Oppo...、Holdings A/S Novo. On average, Entasis Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of 4,855,580$. The most recent stock trade was executed by Inc.Innoviva Strategic Oppo... on 8 July 2022, trading 19,270,476 units of ETTX stock currently worth 42,395,047$.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
Entasis Therapeutics Inc executives and other stock owners filed with the SEC include: